107 results about "Aids patients" patented technology

Cryptosporidium parvum (the cause of cryptosporidiosis) has become one of the most common enteropathogens causing diarrhea worldwide. Symptoms associated with cryptosporidiosis are very debilitating especially in the immunocompromised subject (e.g., AIDS patient). Clinical features include severe, chronic diarrhea, abdominal cramps, fatigue, weight loss, etc. which lead to increased health care costs and increased mortality. There is disclosed herein a method of inhibiting the severity of Cryptosporidium parvum infection by enterally administering a therapeutically effective amount of Lactobacillus reuteri.

A microchannel chip for counting floating microparticles with an optical method is provided. The depth of the microchannel chip is made to be a depth of field such that a clear and sharp optical image of microparticles can be obtained, without necessarily diluting the microparticle mixture inside the microchannel. Consequently, a microparticle counting instrument can easily count microparticles shown on an optical image of the microchannel. Particularly, it enables to count more easily the number of CD3 cells CD4 cells or CD8 cells in white blood cells being stained, without lysing or diluting red blood cells. Therefore, the microchannel chip can advantageously used for counting the number of CD3 cells, CD4 cells or CD8 cells in blood of an AIDS patient to monitor the progression of AIDS.

The present invention provides a pharmaceutical composition for treating patients with HIV infection. The pharmaceutical composition is in the form of an intravenous injection solution and optionally capsules. The pharmaceutical composition contains fourteen (14) ingredients, i.e., diffuse hedyotis, bistort rhizome, giant knotweed rhizome, Asiatic moonseed rhizome, baical skullcap root, bovine biliary powder, milkvetch root, barbary wolfberry fruit, sanqi, figwort root, Chinese magnoliavine fruit, turmeric root-tuber, hawthorn fruit, and Chinese angelica.

The present invention relates to agent containing itraconazole with both improved bioavailability, due to higher water-solubility and impressively reduced difference of pH-dependent solubility, and narrow intra- and inter-individual variation of its absorption- and a manufacturing method thereof. Agent containing itraconazole of the present invention consists of itraconazole, water-soluble macromolecule of 10-100 % w/w to itracotazole, solubilizing agent of 0.1-100 % w/w to itraconazole and pharmaceutically allowed additives. Agent containing itraconazole of the present invention minimizes absorption variation by dozing time after food intake as well as is available for adults with hypoacidity, AIDS patients and normal people. In addition, the manufacturing method introduces the elementary process, the spray drying, thereby control of physical properties of particles containing drug is easier and economy/production is improved.

The invention discloses a Chinese medicine for treating AIDS, which has the functions of fast increasing immunocyte of viral infection AIDS patients, recovering immunological system performance, reducing virus replication, killing AIDS viruses, reinforcing patient constitution and improving patient symptoms.

The invention provides a platform convenient for doctor management and patient self-supervision, and aims to assist a patient to know a health condition and remind the patient to timely go back to a hospital for follow-up visit. The platform has main functions of patient archiving, examination index input, follow-up visit plan and rehabilitation plan pushing and reminding, related follow-up visit data analysis and the like, and provides online expert consultation and wardmate communication, thereby facilitating self-management and self-supervision of the patient. While follow-up visit and diagnosis and treatment process management is covered, data accumulated in an operation process is subjected to statistical analysis, so that big data value is comprehensively reflected and powerful data support and decision support are provided for clinic scientific and research of nephrology departments. The follow-up visit is taken as a center; for the patient with the chronic kidney disease, the follow-up visit is performed in the way; the problem that a kidney disease assistant in China at present takes no count of the follow-up visit is solved; the burden of a doctor and the frequency of going to the hospital for the patient are reduced; and a few unnecessary expenses are saved.

The invention discloses a multi-objective transport path optimization method based on HIV epidemic dynamics. It is assumed that an ecosystem consists of a number of crowds; an HIV virus spreads in the crowds, and people who are in effective contact with people with the HIV virus, are infected with the infectious disease; people who are not infected with the HIV virus are known as susceptible persons; after the susceptible persons are infected with the HIV virus, immediate onset does not occur, and the virus in the body enters an incubation period; people, whose HIV virus is in the incubation period, are known as HIV virus carriers, and such people are divided into two kinds, one kind is people who do not have the disease and have sexual intercourse, the kind of people become AIDS patients after a certain period of time, and ultimately die due to the AIDS; the other kind is people who have never had the disease and lose the sexual intercourse ability, and the kind of people eventually die a natural death; and under the action of the HIV virus, the growth state of each person is randomly changed, and by using the random variation and an HIV epidemic model, a global optimal solution of the multi-objective transport path combined optimization problem can be quickly obtained.

The invention relates to a one-step method preparation process of treatment type drug resistant AIDS (acquired immunodeficiency syndrome) autologous plasma virus inactivated vaccine. Through blood collection, plasma separation and plasma virus inactivation, the vaccine is directly prepared; then, intravenous vaccination is performed; the whole process is completed in a sealed disposable consumable; the pollution risk in the preparation process can be effectively avoided; the vaccine preparation safety is ensured. The preparation process is simple; the cost is low; the inoculation procedure canalso be simplified; the technical requirements of large-dose (600 to 800ml) plasma virus inactivated vaccine inoculation are met. More importantly, the virus strain of the inactivated vaccine is froma patient self; the plasma is also from the patient self; the obvious safety, effectiveness and feasibility are realized. The principle of medical ethics is conformed; the problem of animal model lack of AIDS vaccine development can also be solved. The vaccine is applicable to the continuous treatment of AIDS patients with drug resistance and treatment failure, initial and conventional treatmenton AIDS patients without drug resistance, and emergent blockade treatment on occupational exposure persons.

The invention relates to an application of lyophilized hemsley rockvine root tuber in preparing a medicine used for treating AIDS. The lyophilized hemsley rockvine root tuber can be prepared into any medical preparation with traditional Chinese medicine preparation method. An effective dose for a patient a day comprises 1-300g of lyophilized hemsley rockvine root tuber. Compared with medicines prepared with commonly dried hemsley rockvine root tuber, the medicine prepared by using lyophilized hemsley rockvine root tuber has better functions in enhancing AIDS patient body immunity, inhibiting HIV virus, reducing patient clinical symptoms, and improving patient life qualities. Also, medicine resistance and toxic and side effects when HIV virus is treated by using antiretroviral can be effectively reduced.

The invention relates to the technical field of chemical industry, in particular to a preparation method and application of micromolecule compound with HIV resisting activity. CyPA is able to combine with the Gag polymer protein in HIV-1. Silence or inhibit the activity of CypA with RNAi technology and disturb the replication of virus. The micromolecule compound in the invention refers to a CyPA inhibitor that has the effect of resisting HIV-1 virus. Besides, as the micromolecule compound is designed while aiming at cellular target, the invention is not easy to develop drug resistance, thus meeting the demands of lifetime medication for AIDS patients. Therefore, the micromolecule compound in the invention, which can be developed as a new type anti-AIDS drug, provides a new means for treating and curing AIDS.

The invention relates to an AIDS based preparation method of three-dimensional faulting specimens for researching and teaching. The preparation method is characterized by comprising the following steps: preparing the operation environment and operation conditions; shaping a corpse specimen of an AIDS patient, and pouring a formalin solution through femoral artery intubation for anticorrosion; after pouring the formalin solution into the corpse specimen, placing for 10-12 hours, and fully soaking the corpse in a formalin solution with the weight ratio of 5% for fixing for 6 months; positioning and scribing on the corpse specimen surface in the methyl violet elastic line method; placing the corpse specimen at the environment of -30 DEG C for freezing for 7-10 days; sawing the corpse specimen through a wood serrulate band saw for traverse, coronary and sagittal faulting specimens; conducting pathologic sampling on the faulting specimens; processing and preserving the specimens. The AIDS three-dimensional faulting specimens prepared through the preparation method realize the general perfect combination of the faulting specimens, CT images and pathological corroboration.

The present invention discloses AIDS treating Chinese medicine capsule and its preparation process, and relates to HIV treating medicine. The medicine is prepared with eight kinds of Chinese medicinal materials, including pearl, astragalus root, trichosantes root, licorice, flavescent sophora root, etc in certain weight proportion, and through grinding the Chinese medicinal materials, encapsulating and other steps. It has functions of benefiting Qi, nourishing Yin, cooling blood, detoxicating, clearing away heat, etc, and can inhibiting HIV and strengthen immunity, and has no toxic side effect.

The invention discloses a Chinese medicinal preparation for treating acquired immune deficiency syndrome (AIDS) and a preparation method thereof. The Chinese medicinal preparation is prepared from the following raw materials of baical skullcap root, sophora flower, astragalus, Chinese angelica, siberian solomonseal rhizome, prepared rehmannia root, liquoric root, weeping forsythia, Chinese caterpillar fungus and citric acid in a weight ratio. The Chinese medicinal preparation has the effects of clearing heat and removing toxicity, strengthening body resistance to eliminate pathogenic factors,activating blood circulation and tonifying qi, is used for human immunodeficiency virus (HIV) infected persons and AIDS patients, has an effect of improving cluster of differentiation 4 (CD4) lymphocyte count, can reduce the HIV viral load of peripheral blood gradually, improve the symptoms of the patients obviously and improve liver functions of the patients, and does not have toxic or side effects of antiviral medicines in western medicines.

The invention relates to HIV chimeric gene formed by the union of fragments of different genes of said virus, wherein said fragments contains epitopes for cytotoxic T cells (CTL) or HIV-1 auxiliary T cells, which are presented by a wide range of antigens of type Major Histocompatibility Complex (HLA-I). Recombinant poxviruses are obtained from said genes, which are useful for prophylactic and therapeutic vaccination against HIV/AIDS infections, are capable of generating a protective immune cell response in vaccinated laboratory animals and are recognized by the CTL lymphocytes of HIV/AIDS patients.

The invention relates to the technical field of chemical industry, in particular to a preparation method and application of micromolecule compound with HIV resisting activity. CyPA is able to combine with the Gag polymer protein in HIV-1. Silence or inhibit the activity of CypA with RNAi technology and disturb the replication of virus. The micromolecule compound in the invention refers to a CyPA inhibitor that has the effect of resisting HIV-1 virus. Besides, as the micromolecule compound is designed while aiming at cellular target, the invention is not easy to develop drug resistance, thus meeting the demands of lifetime medication for AIDS patients. Therefore, the micromolecule compound in the invention, which can be developed as a new type anti-AIDS drug, provides a new means for treating and curing AIDS.